Multiple hypertension drugs including Irbesartan, Losartan, and Valsartan, have been recalled in the United States and Europe due to chemical impurities. Following the US and Europe’s lead, the National Agency for Drug and Food Control of the Republic of Indonesia (BPOM) has also ordered their recall.
At mClinica, we wanted to find out whether pharmacists in Indonesia are prepared to execute this drug recall. So, last month we polled 492 pharmacy professionals in Indonesia using SwipeRx surveys, and uncovered the following data:
Most pharmacists knew about the recall but did not have training on how to respond
According to our poll, more than 85% of respondents are aware of the drug recall ordered by BPOM, but the majority of them have received no formal training on how to deal with drug recalls in pharmacies.
More specifically, only 23% of the respondents say that they received formal training on how to deal with drug recalls in pharmacies, and only 24% of the respondents received formal training in patient counselling during drug recalls.
Pharmacists need online education for drug recalls
Not only did our poll show that pharmacists are missing proper training for drug recalls, but it also revealed that training opportunities themselves are lacking. Indeed, the few respondents in our poll who had received training reported that they trained at a school/university, seminar/lecture, or at their workplace.
Offline training events like these are inefficient for many reasons; namely, they require people to take time off work to travel to them, they cost money for both organizers and participants, and they can only train a limited amount of people.
Thankfully, mClinica provides pharmacy professionals with free accredited CPD modules that are accessible anytime and anywhere through the SwipeRx mobile app.
Ultimately, it is clear that pharmacists in Indonesia are in need of drug recall training. One of the barriers to receiving this training is the fact that offline training opportunities are sparse and inefficient. Organizations should consider the promise of mobile learning modules in order to protect patients in the event of drug recalls.